On November 3, 2015, Tufts Center for the Study of Drug Development (CSDD) published its November/December Tufts CSDD Impact Report. According to the report, when “first-in-class” drugs receive market approval a number of follow-on products are already well into the regulatory process.
The study analyzed 40 different classes of pharmaceutical products, including both drugs and biologics from 1998 – 2011 and found:
- 83% of all later-in-class drugs had at least initiated Phase II clinical testing abroad or in the U.S. prior to U.S. marketing approval for the first-in-class drug.
- All later-in-class drugs had a patent filed somewhere in the world before the first-in-class drug was approved in the United States; 96% had a U.S. patent filed before first-in-class approval.
- More than half of all later-in-class drugs received a ‘priority rating’ from the FDA.
According to the report, the race for marketing approval among these products is increasingly competitive. Jopseph DiMasi, Ph.D., Director of Economic Analysis & Research Associate Professor at Tufts CSDD, noted that the development of first-in-class drugs oftentimes begins later than that of competitive drugs in the same class.
Study results show by the time first-in-class approval is granted, the “later-in-class” products are in the following stages of development:
| |
1998 – 2011 |
2005 – 2011 |
| Phase I |
66% |
90% |
| Phase II |
60% |
83% |
| Phase III |
42% |
57% |
Half of all later-in-class products were approved within 2.7 years of first-in-class products that were approved between 1998 and 2011. That same timeframe was reduced to 2.3 years for first-in-class products approved between 2005 and 2011.
DiMasi’s bottom line is that drug development is a “competitive race.” This race occurs “before regulatory success for any drug in the class has been established.”
Are you in the process of developing or obtaining approval for a first-in-class or later-in-class product? Using our proprietary approach, we can help you get through FDA cheaper, faster, and better. To learn more about how we can help you, please contact us.